On the Role of Dendritic Cells Versus Other Cells in Inducing Protective CD8+ T Cell Responses.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Intradermal immunization with Plasmodium berghei late-arresting genetically attenuated sporozoites induces PD-L1 expression on regulatory macrophages and dendritic cells.Scientific reports · 2025
   Article
2. Self-Assembling Protein Nanoparticles in the Design of Vaccines: 2022 Update.Vaccines · 2022
   Review
3. Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use.Journal of leukocyte biology · 2020
   Article
4. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.Expert review of vaccines · 2018
   Review
5. Effective Priming of Herpes Simplex Virus-Specific CD8Journal of virology · 2018
   Article
6. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2017
   Article
7. LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.Molecular therapy oncolytics · 2016
   Article
8. CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells.Proceedings of the National Academy of Sciences of the United States of America · 2015
   Article
9. Effects of dexmedetomidine on cellular immunity of perioperative period in children with brain neoplasms.International journal of clinical and experimental medicine · 2015
   Article
10. Mining the resource of cross-presentation.Frontiers in immunology · 2014
    Article
11. The role of tumor/dendritic cell interactions in the regulation of anti-tumor immunity: the good, the bad, and the ugly.Frontiers in immunology · 2014
    Article
12. Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway.Oncoimmunology
    Article
13. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.Journal of immunotherapy (Hagerstown, Md. : 1997)
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as